Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-07-04T16:06:10.951Z Has data issue: false hasContentIssue false

Pathological Laughter Following Intravenous Sodium Valproate

Published online by Cambridge University Press:  18 September 2015

P.C. Jacob*
Affiliation:
Department of Medicine (Neurology), College of Medicine, Sultan Qaboos University, Muscat, Oman.
R. Pratap Chand
Affiliation:
Department of Medicine (Neurology), College of Medicine, Sultan Qaboos University, Muscat, Oman.
*
College of Medicine, Sultan Qaboos University, P.O. Box 35, PC 123, Muscat, Oman
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Pathological laughter can be a sign of epilepsy, psychiatric illness, effect of toxins or psychotropic drugs or of structural brain disease.

Method:

Case Studies.

Result:

Two patients developed inappropriate uncontrollable laughter following intravenous sodium valproate for treatment of epilepsy.

Conclusion:

Pathological laughter can be a side effect of intravenous sodium valproate.

Type
Original Articles
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

1.Devinsky, O, Leppik, I, Wilmore, LJ, et al. Intravenous Valproate Study Team. Safety of intravenous valproate. Ann Neurol 1995; 38: 670674.CrossRefGoogle Scholar
2.Black, DW. Pathological laughter: a review of the literature. J Nerv Ment Dis 1982; 170: 6771.CrossRefGoogle Scholar
3.Zellers, GL, Frank, M, Daugherly, J. Pathological laughter. Ann Emerg Med 1990; 19: 327329.CrossRefGoogle ScholarPubMed
4.Gascon, GG, Lombroso, CT. Epileptic (gelastic) laughter. Epilepsia 1971; 12: 6376.CrossRefGoogle ScholarPubMed
5.Breningstall, GN. Gelastic seizures, precocious puberty and hypothalamic hamartoma. Neurology 1985; 35: 11801183.CrossRefGoogle ScholarPubMed
6.Saitoh, S, Nickawa, N. The GABA A receptor beta 3 subunit gene (GABRB 3) as a candidate responsible for the central nervous disturbances in Angelman syndrome (AS). Nippon-Rinsho 1993; 51: 240924113.Google Scholar